Passage Bio Stock Buy Hold or Sell Recommendation
| PASG Stock | USD 0.51 0.03 5.56% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Passage Bio is 'Strong Sell'. Macroaxis provides Passage Bio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PASG positions.
Check out Passage Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide. Note, we conduct extensive research on individual companies such as Passage and provide practical buy, sell, or hold advice based on investors' constraints. Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Passage |
Execute Passage Bio Buy or Sell Advice
The Passage recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Passage Bio. Macroaxis does not own or have any residual interests in Passage Bio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Passage Bio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Passage Bio Trading Alerts and Improvement Suggestions
| Passage Bio generated a negative expected return over the last 90 days | |
| Passage Bio has high historical volatility and very poor performance | |
| Passage Bio has some characteristics of a very speculative penny stock | |
| Passage Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (102.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (78.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Vestal Point Capital, LP Increases Stake in Passage Bio Inc |
Passage Bio Returns Distribution Density
The distribution of Passage Bio's historical returns is an attempt to chart the uncertainty of Passage Bio's future price movements. The chart of the probability distribution of Passage Bio daily returns describes the distribution of returns around its average expected value. We use Passage Bio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Passage Bio returns is essential to provide solid investment advice for Passage Bio.
| Mean Return | -0.33 | Value At Risk | -9.88 | Potential Upside | 9.33 | Standard Deviation | 5.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Passage Bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Passage Stock Institutional Investors
| Shares | Fiduciary Trust Co | 2024-09-30 | 215 K | Citadel Advisors Llc | 2024-06-30 | 158.3 K | Rbf Llc | 2024-06-30 | 142.8 K | State Street Corp | 2024-06-30 | 123.9 K | Two Sigma Investments Llc | 2024-06-30 | 103.9 K | Marquette Asset Management Inc. | 2024-06-30 | 85.5 K | Northern Trust Corp | 2024-09-30 | 40.3 K | Goldman Sachs Group Inc | 2024-06-30 | 27.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 26.9 K | Orbimed Advisors, Llc | 2024-06-30 | 10.1 M | Vestal Point Capital Lp | 2024-06-30 | 6.1 M |
Passage Bio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Passage Bio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Passage Bio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Passage stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | 2.32 | |
σ | Overall volatility | 5.72 | |
Ir | Information ratio | -0.08 |
Passage Bio Volatility Alert
Passage Bio exhibits very low volatility with skewness of -0.14 and kurtosis of -0.5. Passage Bio is a potential penny stock. Although Passage Bio may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Passage Bio. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Passage instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Passage Bio Fundamentals Vs Peers
Comparing Passage Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Passage Bio's direct or indirect competition across all of the common fundamentals between Passage Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Passage Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Passage Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Passage Bio to competition |
| Fundamentals | Passage Bio | Peer Average |
| Return On Equity | -0.64 | -0.31 |
| Return On Asset | -0.34 | -0.14 |
| Current Valuation | (25.9 M) | 16.62 B |
| Shares Outstanding | 61.77 M | 571.82 M |
| Shares Owned By Insiders | 0.49 % | 10.09 % |
| Shares Owned By Institutions | 59.68 % | 39.21 % |
| Number Of Shares Shorted | 1.64 M | 4.71 M |
| Price To Book | 0.46 X | 9.51 X |
| EBITDA | (98.34 M) | 3.9 B |
| Net Income | (102.06 M) | 570.98 M |
| Cash And Equivalents | 239.25 M | 2.7 B |
| Cash Per Share | 4.39 X | 5.01 X |
| Total Debt | 26.29 M | 5.32 B |
| Debt To Equity | 0.11 % | 48.70 % |
| Current Ratio | 9.23 X | 2.16 X |
| Book Value Per Share | 2.02 X | 1.93 K |
| Cash Flow From Operations | (78.26 M) | 971.22 M |
| Short Ratio | 6.61 X | 4.00 X |
| Earnings Per Share | (1.17) X | 3.12 X |
| Target Price | 7.67 | |
| Number Of Employees | 58 | 18.84 K |
| Beta | 1.2 | -0.15 |
| Market Capitalization | 33.11 M | 19.03 B |
| Total Asset | 150.54 M | 29.47 B |
| Retained Earnings | (594.47 M) | 9.33 B |
| Working Capital | 101.62 M | 1.48 B |
| Current Asset | 144.91 M | 9.34 B |
| Current Liabilities | 3.09 M | 7.9 B |
| Net Asset | 150.54 M |
Note: Disposition of 50000 shares by Forman Mark S of Passage Bio subject to Rule 16b-3 [view details]
Passage Bio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Passage . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 42886.71 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 0.53 | |||
| Day Typical Price | 0.52 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.03) |
About Passage Bio Buy or Sell Advice
When is the right time to buy or sell Passage Bio? Buying financial instruments such as Passage Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Passage Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Passage Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.